5-amino-2-chloro-4-fluoro-N-(5-(3-(4-hydroxycyclohexanecarboxamido)prop-1-ynyl)-2-(4-methylpiperazin-1-yl)phenyl)-3-methylbenzamide

ID: ALA4877455

PubChem CID: 164627738

Max Phase: Preclinical

Molecular Formula: C29H35ClFN5O3

Molecular Weight: 556.08

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: Cc1c(F)c(N)cc(C(=O)Nc2cc(C#CCNC(=O)C3CCC(O)CC3)ccc2N2CCN(C)CC2)c1Cl

Standard InChI: InChI=1S/C29H35ClFN5O3/c1-18-26(30)22(17-23(32)27(18)31)29(39)34-24-16-19(5-10-25(24)36-14-12-35(2)13-15-36)4-3-11-33-28(38)20-6-8-21(37)9-7-20/h5,10,16-17,20-21,37H,6-9,11-15,32H2,1-2H3,(H,33,38)(H,34,39)

Standard InChI Key: QDIHXTGBZAYDNY-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 39 42  0  0  0  0  0  0  0  0999 V2000
    8.5133   -3.2720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2165   -3.6865    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2090   -4.5037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4942   -4.9063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7910   -4.4918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7985   -3.6746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9123   -4.9182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6230   -4.5156    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9048   -5.7353    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1940   -6.1379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1865   -6.9551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1749   -7.7722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1674   -8.5893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8747   -9.0039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8672   -9.8210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1524  -10.2236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4491   -9.8091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4566   -8.9920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1449  -11.0408    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8481  -11.4553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8406  -12.2724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1298  -12.6750    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4266  -12.2605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4341  -11.4434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1223  -13.4922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2812   -9.8370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9844  -10.2515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6951   -9.8489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3984  -10.2634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3909  -11.0806    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6801  -11.4832    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9769  -11.0687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2887   -9.0199    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.5705  -10.2396    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.1132   -9.8608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0982  -11.4951    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   12.7026   -9.0318    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   12.6726  -12.3003    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0948   -3.2590    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  1  6  1  0
  7  8  2  0
  7  9  1  0
  3  7  1  0
 10 11  1  0
 11 12  3  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 13 18  2  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 19 24  1  0
 22 25  1  0
 16 19  1  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 27 32  2  0
 26 33  2  0
 26 34  1  0
 29 35  1  0
 30 36  1  0
 28 37  1  0
 31 38  1  0
 15 34  1  0
 12 13  1  0
  9 10  1  0
  6 39  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 556.08	Molecular Weight (Monoisotopic): 555.2412	AlogP: 3.39	#Rotatable Bonds: 5
Polar Surface Area: 110.93	Molecular Species: NEUTRAL	HBA: 6	HBD: 4
#RO5 Violations: 1	HBA (Lipinski): 8	HBD (Lipinski): 5	#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.75	CX Basic pKa: 7.60	CX LogP: 3.60	CX LogD: 3.19
Aromatic Rings: 2	Heavy Atoms: 39	QED Weighted: 0.33	Np Likeness Score: -1.27

References

1. Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X.. (2021) Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity., 223 [PMID:34225179] [10.1016/j.ejmech.2021.113677]
2. Karatas, Hacer H, Townsend, Elizabeth C EC, Bernard, Denzil D, Dou, Yali Y and Wang, Shaomeng S. 2010-07-22 Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. [PMID:20575550]
3. Bolshan, Yuri Y and 16 more authors. 2013-03-14 Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. [PMID:24900672]
4. Getlik, Matthäus M and 17 more authors. 2016-03-24 Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). [PMID:26958703]
5. Li, Dong-Dong DD and 9 more authors. 2016-08-08 Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. [PMID:27116709]
6. Li, Dong-Dong DD and 8 more authors. 2016-11-29 High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. [PMID:27598236]
7. Li, Dong-Dong DD and 5 more authors. 2016-11-15 Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. [PMID:27720555]
8. Wang, Feng F and 17 more authors. 2018-07-12 Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:29889518]
9. Ye, Xiaoqing X and 11 more authors. 2019-02-15 The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening. [PMID:30626558]
10. Tian, Jianhua and 24 more authors. 2020-01-23 Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. [PMID:31858797]
11. Chacón Simon, Selena and 14 more authors. 2020-04-23 Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:32223236]

5-amino-2-chloro-4-fluoro-N-(5-(3-(4-hydroxycyclohexanecarboxamido)prop-1-ynyl)-2-(4-methylpiperazin-1-yl)phenyl)-3-methylbenzamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source